US 12,453,741 B2
Hydroxypropyl beta-cyclodextrin compositions and methods
Bernardus Nicolaas Machielse, North Potomac, MD (US); and Allan Darling, North Potomac, MD (US)
Assigned to MANDOS LLC, Thousand Oaks, CA (US)
Filed by Mandos LLC, West Hollywood, CA (US)
Filed on Apr. 10, 2025, as Appl. No. 19/175,757.
Application 19/175,757 is a continuation of application No. 18/533,373, filed on Dec. 8, 2023.
Application 18/533,373 is a continuation of application No. 17/970,080, filed on Oct. 20, 2022, granted, now 11,938,144, issued on Mar. 26, 2024.
Application 17/970,080 is a continuation of application No. 17/745,464, filed on May 16, 2022, granted, now 11,590,159, issued on Feb. 28, 2023.
Application 17/745,464 is a continuation of application No. 17/036,148, filed on Sep. 29, 2020, granted, now 11,406,657, issued on Aug. 9, 2022.
Application 17/036,148 is a continuation of application No. 16/430,664, filed on Jun. 4, 2019, granted, now 10,933,083, issued on Mar. 2, 2021.
Application 16/430,664 is a continuation of application No. 16/372,899, filed on Apr. 2, 2019, granted, now 10,709,730, issued on Jul. 14, 2020.
Application 16/372,899 is a continuation of application No. 16/134,028, filed on Sep. 18, 2018, granted, now 10,300,086, issued on May 28, 2019.
Application 16/134,028 is a continuation of application No. 15/499,831, filed on Apr. 27, 2017, granted, now 10,258,641, issued on Apr. 16, 2019.
Application 15/499,831 is a continuation of application No. 15/288,876, filed on Oct. 7, 2016, granted, now 9,675,634, issued on Jun. 13, 2017.
Application 15/288,876 is a continuation of application No. 15/178,153, filed on Jun. 9, 2016, abandoned.
Claims priority of provisional application 62/345,721, filed on Jun. 3, 2016.
Claims priority of provisional application 62/331,385, filed on May 3, 2016.
Claims priority of provisional application 62/314,765, filed on Mar. 29, 2016.
Claims priority of provisional application 62/308,736, filed on Mar. 15, 2016.
Claims priority of provisional application 62/276,728, filed on Jan. 8, 2016.
Claims priority of provisional application 62/263,599, filed on Dec. 4, 2015.
Claims priority of provisional application 62/249,876, filed on Nov. 2, 2015.
Claims priority of provisional application 62/245,974, filed on Oct. 23, 2015.
Claims priority of provisional application 62/189,114, filed on Jul. 6, 2015.
Claims priority of provisional application 62/175,075, filed on Jun. 12, 2015.
Claims priority of provisional application 62/173,889, filed on Jun. 10, 2015.
Prior Publication US 2025/0255899 A1, Aug. 14, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/724 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01)
CPC A61K 31/724 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/08 (2013.01)] 30 Claims
 
1. A composition for intrathecal injection comprising a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein the composition is pharmaceutically acceptable for intrathecal administration, the composition comprises less than 2 Endotoxin Units (EU) of endotoxins per gram, no more than 0.5% propylene glycol, and less than 1 ppm of propylene oxide.